OTCMKTS:BIOVF Q3 EPS Forecast Decreased by HC Wainwright

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) – Stock analysts at HC Wainwright dropped their Q3 2026 EPS estimates for shares of Swedish Orphan Biovitrum in a note issued to investors on Friday, July 17th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of $0.63 per share for the quarter, down from their previous estimate of $0.69. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Swedish Orphan Biovitrum’s current full-year earnings is $1.94 per share. HC Wainwright also issued estimates for Swedish Orphan Biovitrum’s Q4 2026 earnings at $0.60 EPS, FY2026 earnings at $1.94 EPS, Q1 2027 earnings at $0.62 EPS, Q2 2027 earnings at $0.68 EPS, Q3 2027 earnings at $1.05 EPS, Q4 2027 earnings at $1.03 EPS and FY2027 earnings at $3.36 EPS.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.07. Swedish Orphan Biovitrum had a return on equity of 18.27% and a net margin of 4.74%.The firm had revenue of $755.76 million during the quarter, compared to the consensus estimate of $749.76 million.

Other equities research analysts also recently issued research reports about the company. Zacks Research raised Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, May 7th. Pareto Securities lowered Swedish Orphan Biovitrum to a “hold” rating in a research report on Monday, June 29th. Finally, Barclays restated an “overweight” rating on shares of Swedish Orphan Biovitrum in a report on Friday, July 3rd. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

Swedish Orphan Biovitrum Stock Performance

OTCMKTS:BIOVF opened at $49.03 on Monday. The business’s 50-day moving average is $47.95 and its two-hundred day moving average is $42.20. The firm has a market capitalization of $17.45 billion, a PE ratio of 108.95 and a beta of 0.35. Swedish Orphan Biovitrum has a 12 month low of $28.93 and a 12 month high of $49.03. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.70 and a quick ratio of 0.47.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.